Clinical Trial Update: Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer [Phase 2]

View source ↗

Summary

Phase 2 exploratory study evaluating FDG-PET as a predictive marker for RAD001 (everolimus) therapy in metastatic renal cell carcinoma; results have been posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: University of Chicago | Conditions: Carcinoma, Renal Cell | Phase 2 | Status: COMPLETED | Results posted: 2017-11-09